Denali Therapeutics, Inc.

Baillie Gifford is an active, team-oriented, research-based manager which is completely focused on delivering long-term returns. The firm’s investment philosophy focuses on growth while their universe is global. They employ bottom-up conviction to portfolio construction. Their diversified strategies maximize investment opportunities, aiming to achieve steady returns. For equities, Baillie Gifford’s analysts conduct qualitative, fundamental analysis to identify the most competitive, innovative and efficient growth companies. For multi-asset strategy, the firm invests in various asset classes such as listed equities, property, high yield credit, commodities, emerging market government bonds and insurance linked securities. For fixed-income, Baillie Gifford invests in government bonds and currencies, emerging market bonds, investment grade and high yield.

Crestline Management has fund clients that focus on opportunistic investments and credit related investments and fund clients that focus on hedge fund investments. With respect to opportunistic and lending clients, those fund clients will make direct investments in securities, as opposed to via an investment in an underlying private fund, and certain fund clients will invest in middle market loans, whether directly-originated or syndicated loans or loans acquired in other market transactions. With respect to fund clients pursuing hedge fund strategies, Crestline Management manages an equity long/short strategy and also manages diversified hedge fund programs structured as funds of funds. Fund clients that invest in long/short equity strategies allocate assets to sector specialist portfolio managers whose stock selection is generally driven by fundamental analysis. The portfolio is run with controls on net market exposure and other risk factors. Leverage is used in the program to seek to achieve the targeted risk and return levels for the strategy. Fund clients investing in other fund managers generally allocate assets to a variety of portfolio managers through direct investments in underlying private funds or segregated portfolio arrangements, through acquisition of investments in underlying private funds managed by portfolio managers via the secondary market and, in certain instances, through discretionary managed accounts, single purpose entities, entities consisting primarily of Crestline-advised funds or through swaps or other similar products.

Temasek-IM is an active, long-term manager which takes stakes in regional or global companies with significant potential. The firm aims to build companies into profitable operations while promoting sound corporate governance. They do not involve themselves in commercial or operational decisions except to exercise shareholder voting rights and help companies recruit management. Their investment decisions are taken independently of the Singapore Government. Temasek-IM has a long term investment horizon and because they invest off their own balance sheet, they are not constrained by ‘fund life’. As an owner investor, the firm is mostly invested in equities but do not set limits for geographies, sectors, or asset classes. Their global portfolio spans a broad spectrum of industries: financial services; telecommunications, media & technology; consumer & real estate; transportation & industrials; life sciences & agribusiness; as well as energy & resources. Temasek-IM invests in companies based in Singapore, Asia and the OECD countries.

Baillie Gifford is an active, team-oriented, research-based manager which is completely focused on delivering long-term returns. The firm’s investment philosophy focuses on growth while their universe is global. They employ bottom-up conviction to portfolio construction. Their diversified strategies maximize investment opportunities, aiming to achieve steady returns. For equities, Baillie Gifford’s analysts conduct qualitative, fundamental analysis to identify the most competitive, innovative and efficient growth companies. For multi-asset strategy, the firm invests in various asset classes such as listed equities, property, high yield credit, commodities, emerging market government bonds and insurance linked securities. For fixed-income, Baillie Gifford invests in government bonds and currencies, emerging market bonds, investment grade and high yield.

Flagship Pioneering seeks investment opportunities in companies located globally. The firm focuses on companies operating in the fields of therapeutics, life science tools & diagnostics, and bioenergy or cleantech. It provides financing for seed, early, and later-stage capital requirements. It acts as a lead investor. It also makes co-investments.

Impresa focuses on early-stage investments in start-up companies across US and International portfolio companies. There fund focuses on companies operating in the fields of biopharmaceutical, medical technology & healthcare IT and services.There funds are larger and more global. In the US and Europe, they are F-Prime Capital investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, there sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai with over $2 trillion in assets under management.